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INTRODUCTION

This Reply Brief is submitted in response to the Brief of
the Respondent filed with this Court on August 30, 1982. 1
parties have provided Statements of Fact to this Court.
Squibb & Sons,

Inc.

( 11 Squibb 11

)

Both
E.R.

believes that certain "facts 11

related by counsel for the Barsons require correction.

However,

rather than engaging in a point-by-point debate, we will address
these matters at various points throughout this Reply Brief.
1

References to the Briefs and record in this case will be made
in the following manner:
(1) The Brief of Appellant E.R. Squibb & Sons, Inc. filed
on June 30, 1982, will be referred to as "Squibb Brief."
(2) The Brief of the Respondent Elizabeth Ann Barson filed
on August 30, 1982, will be referred to as "Barson Brief."
(3) The Reply Brief of Appellant E.R. Squibb & Sons, Inc.
will be referred to as "Reply Brief."
(4) One volume of separately numbered papers and pleadings
filed in the trial court and designated for inclusion in the
record on appeal will be prefaced by the letter "R."
(5) A separate one-volume transcript of the proceedings at
pretrial will be prefaced by the letters "PR.If
(6) Sixteen volumes of transcript of trial and post-trial
proceedings will be referred to by the abbreviation "Tr."
(7) ·All exhibits received at trial will be referred to by
the Letters "P .Ex." for plaintiffs' Exhibits and 11 0.Ex." for
Squibb's Exhibits.
(8) The Minutes, November 5-6, 1981 Meeting, "Fertility and
Maternal Health Drugs Advisory Committee," Food and Drug Administration admitted as a result of a motion to supplement the record
are included as Appendix A.
(9) Proposed Instruction lOA submitted to the trial court
by Squibb
is included as Appendix B.
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The

appellant and respondent apparently agree that the

critical question presented in the trial court was:

whether in

medical probability Elizabeth Ann Barson' s birth defects were
caused by the administration of Delalutin to her mother?

This

pivotal question was resolved in the Barsons' favor by the jury
after several categories of improperly admitted and highly prejudicial evidence were considered by it.
Squibb does not ask that this Court substitute its views on
the evidence for that of the jury.

Rather, each of the evidentiary

errors related in Squibb's initial Brief were so sigilificant that
the

jury's verdict must be presumed to have been affected.

Cerritos Trucking Co. v. Utah Venture No. 1, 645 P.2d 608 (Utah
1982); Lee v. Mitchell Funeral Home

Ambulance~.,

606 P.2d 259

(Utah 1980) (reversal based on evidential errors appropriate if
there is a reasonable likelihood that in absence of error there
would be a result more favorable to the complaining party).

It

is on this basis that the jury's verdict must be set aside and a
new trial directed.

U.R.C.P. 61; U.R.E. 4(b).

Squibb also has complained that the jury's verdict in this
case must be reversed because it was improperly instructed about
the doctrine of strict liability as applied in a prescription
drug case and that the trial court erred as a matter of law when
it declined to dismiss the claim that Squibb negligently failed
to test Delalutin in animals to determine its teratogenic potential.

Sponsored by the S.J. Quinney Law Library. Funding for digitization
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As will be seen in this Reply Brief, the respondent does not
affirmatively challenge these arguments.

Rather, she now suggests

alternative bases and legal theories for the jury's verdict and
argues that the challenged evidence is admissible on a variety of
alternate grounds not suggested during the trial.
presented here,

For the reasons

and in its initial Brief, Squibb believes these

arguments to be insubstantial.

The judgment below must be reversed

and the appellant granted a new trial.

Sponsored by the S.J. Quinney Law Library. Funding for digitization provided by the Institute of Museum and Library Services
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ARGUMENT
POINT I
THE RESPONDENT FAILS TO PROVIDE THIS
COURT WITH ANY BASIS FOR ADMITTING THE FDA- ,
MANDATED PACKAGE INSERTS.
The FDA-Mandated Physician and Patient
Package Inserts are Inadmissible Hearsay.

A.

The parties both at the trial level and in this Court recognize that a pivotal evidential issue decided adversely to Squibb
was the propriety of admitting in evidence subsequently mandated
physician and patient package warnings.

A review of the trial

record discloses that these warnings were not admitted for limited
purposes such as feasibility,
by the respondent.

impeachment or rebuttal now urged

Compare Barson Brief at 28-34 with PR 45-50,

68-72; Trll93-1197, 1495-1496.

Rather, the trial court admitted

them in support of the respondent's contention that Delalutin was
both an ineffective drug and that its administration could lead
to an incalculable increased risk of birth defects including limb
anomalies.

These judgmental expressions by the FDA were hearsay

and inadmissible except as provided in U. R. E. 63.

The trial
I

judge never resolved the hearsay objections made by counsel for
Squibb.

See Squibb Brief at 26 n. 18. 2

2

The trial judge determined that these FDA-mandated warnings
were not admissions of Squibb. The judge during argument observed
"this I don't think could come in as an admission" (PR. -so).
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The respondent has completely ignored this critical appellate issue in its Brief,

arguing instead that the FDA-mandated

warnings are a form of subsequent remedial conduct which should
be admissible in evidence based upon both legal and policy grounds.
The respondent ignores the fact,
rule of exclusion.

however,

that U.R.E. 51 is a

It. provides for the exclusion of otherwise

admissible evidence on legal and policy grounds, not for the
introduction of otherwise inadmissible evidence.
The FDA warnings from the time of their introduction occupied
a dominant place in this trial.

Squibb Brief at 14-16.

Although

they were clearly used by the plaintiff to convince the jury that
a cause and effect relationship existed between the administration
of Delalutin and birth defects, the FDA, which had mandated these
warnings, eschewed such a purpose.

Rather, the Commissioner of

Food and Drugs, at the time these warnings were mandated, noted
that "it is not possible to draw

~

cause and effect relationship

with progesterone or hydroxxprogesterone
these data."

43 Fed.,

[Delalutin] based on

Reg. 47178 (October 13, 1978) (emphasis

added).
The FDA,

moreover,

had a fundamentally different role to

play than the jury in this case.

In its role as this nation's

public health guardian, the FDA might choose to act on the basis
of incomplete information to protect the public from possible
dangers.

One necessarily expects that such a public agency,

given its mandate,

might act upon incomplete and preliminary

information which may eventually turn out to be erroneous.
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Because none of the circumstances surrounding publication of
these warnings could be properly elicited on cross-examination,
the jury was unfairly left with the impression that this nation's
public health expert had made a judgment that Delalutin was in
fact a teratogen--something which the FDA itself specifically
3
disclaimed. 43 Fed Reg. 47178 (October 13, 1978).
Courts have recognized that an agency's public responsibilities and its actions in implementing them may affect the
reliability of judgmental information contained in its pronouncements.

For example,

in Zenith Radio

.£2.!l?..

v. Matsushita Elec.

3

The appellant believes that it brought to the trial court's
attention evidence which was not available during trial which was
of such significance that had it been available at trial there is
a reasonable likelihood that a different result would have occurred.
That evidence was in the form of a recommendation by the FDA
Fertility and Maternal Drugs Advisory Committee that Delalutin's
labeling be changed to delete the warnings introduced at trial.
Appendix A at 16-17.
While we do not intend to reargue this
issue, several statments by the respondent require correction.
Inexplicably, the respondent advised this Court that "of significance is ... [that] ... specific notice of the hearing was not
published among the members of the medical and scientific coriiiiluility
who take a position on the safety of the drug contrary to Squibb's."
Barson Brief at 46 (emphasis added). This statement is erroneous.
As with all meetings of the Fertility and Maternal Health Drugs
Advisory Committee a formal notice of the meeting and subjects
open for discussion were published in the Federal Register.
Moreover, the notice provided instructions regarding reimbursement
for those who wished to attend and present testimony.
See 46
Fed. Reg. 51033-51034 (October 15, 1981).
~
The respondent has quoted at length from the testimony of
Dr. Eve Bargmann, a physician representing Public Citizen Health
Research Group. What is significant is that following Dr. Bargmann's
testimony the Committee continued to recommend that the FDA
modify Delalutin's labeling by removing the warnings introduced
in evidence in this case.
It is this recommendation which, if
hearsay is to be admitted in the form of mandated package inserts,
is relevant and was available to meet the conclusions which the
respondent sought to draw from them--that Delalutin caused birth
defects.
Sponsored by the S.J. Quinney Law Library. Funding for digitization provided by the Institute of Museum and Library Services
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Ind. Co., SOS F. Supp. 112S, 1147-llSO (E.D. Pa. 1980), a Federal
District Court found that an agency's regulatory posture may cause
potential problems affecting the reliability of its findings.

In

declining to receive a detailed report made by the Department of
Commerce as evidence in a major antitrust case, the Zenith Court
explained this phenomenon:
[T]he extent to which ... findings are a
function of an executive, administrative or
legislative policy judgment or represent an
implementation of policy ... [presents]
a
variation on the theme of "motivational
problems" identified as one of the Advisory
Committee's trustworthiness criteria ...
In
our view, where there exists within an agency
a preconceived notion of the policy that the
agency is attempting to implement
the
11
findings" of that agency are to at least
some degree a function of that preconceived
notion, and though they may be "trustworthy"
in light of the particular policy objectives
the agency is attempting to further, they may
or may not be trustworthy for other purposes.
overriding policy concerns bring into question
the objectivity of an agency's finding ....
oo•

o

o

•

•

Zenith Radio £2.!:E,. v. Matsushita Elec. Ind. Co., 505 F. Supp. at
1148-1149.

4

In sum, the respondent has failed to provide a basis for the
admissibility of this unreliable hearsay information at the trial
level or here.

Any legal or policy arguments made to this

4

The judgments reflected in the FDA mandated physician and
patient package inserts were also based upon information which
itself is in the process of evolution.
As reflected in the
recent recommendation of the FDA Committee responsible for evaluating the safety and efficacy of drugs used in pregnancy, information
developed since the warnings were implemented has led that Committee to suggest that Delalutin's labeling be changed to omit these
warnings.
The FDA currently has this Committee's recommendation
under advisement. Appendix A at 16-17.
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Court respecting the admission of subsequent remedial measures in
strict liability cases cannot operate to permit the receipt of
otherwise inadmissible evidence.
B.

The Post-1972 Physician and Patient Package
Inserts Are Neither Relevant on the Issue of
Causation Nor Should They Be Admitted on
Public Policy Grounds.

The respondent asks that this Court decline to follow U.R.E. 51
in strict liability cases.

U.R.E. 51 which excludes evidence of

subsequent remedial conduct is based upon two concerns.

First,

the evidence is of questionable relevance since subsequent actions
are not necessarily consistent with prior knowledge and/or culpable
conduct.

Second,

permitting the introduction of evidence of

remedial measures is likely to discourage them, particularly in
close cases.

This Court has agreed with both concerns in its

previous decisions.

The respondent, however, suggests that these

policies have less value in a strict liability context.
courts,

however,

Most

which have considered the matter disagree. 5

5

As noted in our initial brief, the rule in Ault v. Int'l
Harvester, !!!£., 528 P.2d 1148 (Cal. 1974), appears to be the
minority one.
It apparently has been adopted by the United
States Court of Appeals for the Eighth Circuit and the courts of
New York and South Dakota. Since our initial brief was filed the
Supreme Court of Wyoming has suggested in dicta that the Ault
rule should be adopted in Wyoming. See "Caldwell v. YamahaMO'tOr
Co. Ltd. of Japan, 648 P.2d 519 (Wy0:---1982).
As noted in our
initial brief, the United States Courts of Appeals for the First,
second, Third, Fourth, Sixth and Seventh Circuits have determined
that subsequent remedial conduct is not admissible in strict
liability actions.
See Squibb Brief at 41-42.
In addition,
courts in the States of Indiana, Michigan, New Jersey, Ohio,
Texas, Washington and Wisconsin have excluded evidence of subsequent warnings in strict liability cases.
Since the filing of
Squibb's initial brief an Appellate court in Arizona has also
Sponsored by the S.J. Quinney Law Library. Funding for digitization
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Prior to the enactment of U.R.E. 51,

this Court determined

that subsequent remedial conduct is not admissible because it
"does not establish or tend to establish knowledge ....

Rather,

it seems to negative such knowledge and well may have evidenced a
desire to prevent

[injuries] . "

Co., 235 P.2d 525, 527 (Utah 1951).

Bennett v.

Pilot Products

In a strict liability prescrip-

tion drug case involving a failure to warn, knowledge, of course,
is a vital issue.

Thus, the relevance concerns expressed over 30

years ago by the Bennett court have the same vitality today.
also,

~.,

See

Ortho Pharmaceutical Corp. v. Chapman, 388 N.E.2d

541, 561-562 (Ind. App. 1979).
The question of relevance of these warnings to the issue of
causation is particularly important in this case where the author
of the warnings, the FDA, denies that they report a cause and effect
relationship between Delalutin and teratogenic effects.

Since at

least one significant purpose served by the provisions of U.R.E. 51
is to prevent the receipt of irrelevant evidence, excluding these
FDA warnings is appropriate.
The second policy reason supporting the exclusionary rule
reflected in U.R.E. 51 is the recognition that people are loath
to take actions which increase the risks of losing a lawsuit.

The

exclusion of subsequent remedial conduct is based on a societal
5 (Cont'd)
found that the policies expressed in its rule excluding subsequent
remedial conduct were applicable in a products liability case
involving strict liability.
See Hallmark v. Allied Products
£2!:p_., 646 P.2d 319 (Arizo Ap~1982) (the Arizona rule is the
same as Fed. R. Evid. 407).
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judgment that excluding such evidence will encourage prompt remedial

conduct especially in equivocal situations.

See,

~.

,

Potter v. Dr. W.H. Groves Latter-Day Saints Hospital, 103 P.2d
280, 282 (Utah 1940).
F. 2d 848,
( 1981) .

~also,

Werner v. Upjohn Co., Inc., 628

857-858 · (4th Cir. 1980), cert. denied 449 U.S. 1080
The responent has suggested that U. R. E. 51 does not

require exclusion of evidence of subsequent remedial actions in
a strict liability action.

Although adoption of comments h, j

and k to the Restatement of Torts (2d) § 402A by this Court will
obviate such an argument, this Court should not get the misimpression that the policies expressed in U.R.E. 51 are inapplicable
where strict liability is involved.

6

The respondent suggests that by its terms U.R.E. 51 is inapplicable because evidence of subsequent measure is only rendered
inadmissible to prove "negligence" or

11

culpable conducto"

This

Court has already answered this argument in a different context
when it found that semantic difficulties in comparing strict
liability and negligence should not obscure
expressed in the law.
1301,

Mulherin v.

1304 (Utah 1981).

th~

policy objectives

Ingersoll-Rand Co., 628 P.2d

It would seem then that if similar

policies are reflected in excluding subsequent remedial conduct
both in a negligence and strict liability matter, the exclusionary
rule should be applied.
6

In. the Squibb Brief at 36-37 it is suggested that the Restatement of Torts (2d) § 402A comments h, j and k provide that Squibb's
duty to warn in a drug case should be measured by traditional
concepts of negligence.
Therefore, by its terms U.R.E. 51 is
applicable to this case.
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Using this rationale the vast majority of courts which have
considered this issue have applied the exclusionary rule in a
strict liability context.

This approach was explained by the

Second Circuit in Cann v. Ford Motor Co., 658 F.2d 54, 60 (2d
Cir. 1981), cert. denied,

U.S.

, 102 s.ct. 2036 (1982),

in the following way:
Appellants point out that a negligence action
places in issue whether the defendant's
conduct was reasonable while a strict liability
action involves whether the product was defective; they note that the jury focuses on the
defendant in the negligence action, but solely
upon the product in a strict liability action.
However, the defendant must pay the judgment
in both situations, regardless of where the
jury's attention focused when they found against
him. Since the policy considerations underlying[the rule excluding remedial conduct]-not to
discourage persons from taking remedial measures
is relevant to defendants sued under either
theory, we do not see the significance of the
distinction.
A potential defendant must be
equally concerned regardless of the theoretical
rubric under which this highly prejudicial ...
and extremely damaging evidence
is admitted.
[Id. at 60; citations omitted; emphasis in the
original]
oo•

The respondent suggests that the public policy behind U.R.E. 51,
however, should be suspended when the subsequent remedial conduct is
in the form of warnings mandated by a governmental agency.

7

This

argument is not supported by the cases cited by the respondent.
7

This position is actually supportive of Squibb's argument
that the warnings themselves are inadmissible hearsay. Certainly
it is difficult to contend that where warnings are mandated by a
governmental authority under law that compliance with that mandate
constitutes an admission. See ~· Lindsay v. Ortho Pharmaceutical
.£.Q.fE.., 637 F.2d 87, 94 (2d Cir. 1980); Squibb Brief at 30-32.
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Instead, Werner v. Upjohn Co., Inc., 628 F.2d at 848, is dispositive.
In that case the Fourth Circuit explained that in areas involving
drug regulation the FDA relies upon full participation by the
various drug companies and encourages voluntary action in advance
of regulation. 8

These policies would be frustrated were the

exclusionary rule to be held inapplicable in drug related cases.

9

8

The respondent seeks to distinguish Werner suggesting that
the drug in that case was a "new" drug while Delalutin was a drug
which had been marketed for many years and was not a "new" drug.
The respondent misunderstands the term "new drug." 21 U.S. c.
§ 321 (p) defines the term "new drug."
Delalutin is, in fact, a
new drug under the Federal Food Drug and Cosmetic Act (FFDC) and
is subject to regulation as such. For a more complete discussion
of the drug regulatory scheme in the United States and the differences between various provisions of the FFDC, see United
States v. Article of Drug ... Hormonin, 498 F. supp:-424 (D.N.J.
1980), aff'd o.b., 672 F.2d 902 (3d. Cir. 1981).
9

The respondent erroneously cited Rozier v. Ford Motor Co.,
573 F.2d 1332 (5th Cir. 1978), for the proposition that no public
policy is served by excluding subsequently mandated governmental
warnings.
Rozier did not so hold.
That case involved a motion
for a new trial based upon Ford Motor Company's failure to produce
on discovery certain memoranda dealing with the placement of the
gas tank in various Ford Pinto models.
In directing a new trial
the Fifth Circuit found that Ford had been grossly negligent or
contumacious when it withheld information concerning this issue.
In dicta, the Court found that the federal exclusionary rule with
respect to subsequent remedial conduct did not preclude these
documents from being introduced in evidence because the documents
themselves were prepared two years before the accident and thus
were not remedial measures.
The Fifth Circuit also observed in
dicta that the material, if it had been made available to the-plaintiff, might have been admissible as proof of subsidiary
issues such as knowledge or feasibility.
However, the Court
concluded:
We cannot know what use, if any, plaintiff's
counsel would have made of the Trend Cost Estimate had it been produced by Ford prior to
trial.
[Id. at 1343]
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C.

None of the Judicially Created Exceptions
to the Exclusionary Rule on Subsequent
Remedial Conduct are Applicable Here.

The respondent argues that the improper admission of these
FDA warnings can be rationalized on other grounds and thus any
errors committed by the trial court were harmless.

U.R.C.P. 61.

She now urges this Court to approve the admission of this highly
prejudicial evidence to establish the feasibility of conveying
warnings and as proper impeachment and rebuttal evidence.

The

short answer to those suggestions is that this Court may not
speculate as to how the trial would have proceeded had the court
below correctly declined to receive this hearsay evidence.

Those

matters can only be dealt with at the retrial of this case.
The respondent attempts to inject £easibility as a legitimate
issue in this case.

The record belies that suggestion.

It was

only after the jury verdict that the admission of these FDA-mandated
warnings was seriously defended on this ground (Tr. 2623).
The respondent suggests that Love v. Wolf, 58 Cal. Rptr. 42
(Cal. Ct. App. 1967), permits the receipt of these FDA-mandated
warnings on this issue.

That case presents vastly different

issues than exist here.

In Love, a California appellate court

permitted the receipt of subsequent warnings as impeaching evidence
when various drug company officials contended that it was not
possible to prepare clearer warnings.

The Love case is emblematic

of a number of decisions which have permitted subsequent warnings
to be introduced in evidence where the clarity of a prior warning
is a contested issue and the subsequent warning tends to establish
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the feasibility of conveying a clearer warning.

That issue was

not present here.
Here,

Squibb contended that Delalutin was not a teratogen

and therefore no warning was either necessary or appropriate.
Squibb also argued that there was insufficient knowledge in July
1972 for any responsible drug company to publish such a teratogenici ty warning.

The information in the subsequently mandated
10
FDA warnings addressed neither of those issues.

10
As previously noted there is no dispute that Squibb could
physically publish a warning. Nor was there any issue raised at
trial that Squibb failed to publish a clear warning.
Thus the
feasibility of doing either was never in dispute.
To the extent it is suggested that it was feasible to discover
a potential teratogenicity danger and to warn through labeling,
the record reveals that no articles had appeared prior to the
administration of Delalutin to the plaintiff's mother in July
1972 suggesting an association between progestins generally and
limb anomalies. The only literature appearing before 1972, cited
in the subsequent FDA mandated warnings, dealing with any potential
teratogenic effects of progestins was a one page letter from Dr.
Isabel Gal in 1967. Gal, Nature Vol. 216:83 (October 7, 1967).
This letter, in part, reported a statistical association
between babies born with neural tube or spinal defects (not limb
anomalies) and mothers who had been given hormonal pregnancy
tests.
It also observed that "[t]he possibility cannot be excluded
that the difference significant at the 1% level between the two
groups of mothers whom we questioned might emerge purely by
chance." Gal, Nature, Vol. 216:83 (October 7, 1967).
(Tr. 814)
However, certain things were clear. First, the drug, a hormonal
pregnancy test, a combination of progestin and estrogen, was
different than Delalutin.
(Tr. 812-813)
Second, the progestin
in these hormonal pregnancy tests was not Delalutin.
(Tr. 818)
Third, a basic error, obvious on the face of the paper, made the
article biologically implausible.
(Tr. 849) Gal noted, "[t]he
average interval between conception and test was 5.6 weeks in the
survey group [babies with defects] and 6.2 weeks in the control
group." Gal realized that in order to have any meaning the drug
had to have. been administered before the clo~ing of the neural
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It is also evident that the respondent's potpourri of other
grounds

for

purposes,

admission,

such as

for impeachment and rebuttal

are pretextual given the state of the record. 11

Since

10 (Cont'd)
tube.
Gal did not know, however, that based upon the dates she
reported, a large proportion of mothers in the survey received
the hormones after the critical period where i t could affect
closure of the neural tube..
(Tr. 849) A subsequent publication
by Oro Lowell E .. Sever of the Department of Epidemiology, University of Washington, Seattle, Washington, pointed out this obvious
deficiency.
Sever, "Hormonal Pregnancy Tests and Spina Bidifa,"
Nature, Vol. 242:410-411 (1973).
(Tr. 848-849)
Thus, i t is clear that, while Gal reported an association:
(l) by definition, and by her own admissions, it was not causation;
(2) by her admission i t could have been due to chance alone; and
( 3) because of observation errors in the calculation of the
timing of the birth defects, the study's biological plausibility
was cast in doubt.,
(Tr. 849, 2410)
The difficulties with Gal's work in fact were so pronounced
that Dr., Allen Goldman, an expert witness for the plaintiff
observed:
I didn't discuss the validity of her
work.
In fact I don't think that neural tube
defect data are that clear.
(Tr. 2410)

It is evident that both in reality and on the state of this
record the Gal letter could not and did not provide Squibb with
knowledge that progestins generally caused limb anomalies.
It
certainly did not establish the possibility of giving warnings
and cannot justify the admission of FDA mandated warnings made 10
years _after the appearance of the Gal letter.
11
Love v. Wolf, 58 Calo Rptr. at 42 stressed that the warnings
were admitted for impeachment purposes and the jury was charged
as to how those subsequent warnings should be considered by it.
This also was the case in Incollingo v. Ewing, 282 A .. 2d 206, 222
(Pa. 1971), where the Pennsylvania Supreme Court permitted the
receipt of subsequent warnings..
There, the drug company had
suggested that the warning in effect at the time the drug was
administered was adequate.
In permitting this evidence to be
considered by the jury, the Pennsylvania Supreme Court stressed
that "the jury was thrice instructed that the .... [subsequent] ....
warning was not to be taken as evidence bearing on antecedent
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the FDA mandated warnings were introduced in evidence during the
12
respondent's direct case, Squibb had to confront them.
The
error was made by the trial court during the plaintiff's direct
case. 13
In sum, the plaintiff has failed to demonstrate any substantial basis for admitting the FDA physician and patient package
inserts in evidence.

These documents once admitted were repeatedly

11 (Cont'd)
negligence.
It is also important to note that in Incollingo one
of the issues raised by the plaintiffs and presented to the jury
was the fact that the ambiguous warning existing at the time the
drug was prescribed was in effect cancelled when detail men from
the drug company overpromoted the drug. None of these issues
were present in this case.
12
The respondent inexplicably cites Givens v. Leder le, 556
F.2d 1341 (5th Cir. 1977), and Reyes v. Wyeth Laboratories, Inc.,
498 F.2d 1264 (5th Cir. 1974), cert. denied, 419 U.S. 1096 (1974)
as permitting the introduction~ subsequent warnings on the
issue of causation.
Barson Brief at 34.
The respondent is
simply inaccurate~
In Givens the Fifth Circuit approved the
introduction of statistical reports from the Center for Disease
Control, a United States government agency.
The exhibits, the
1971 and 1972 Annual Poliomyelitis Summaries, were not introduced
to show that the vaccine in issue caused polio.
Rather, the
documents, which appear to have been statistical summaries, were
introduced on the limited issue "of whether the medical profession
recognized that vaccine-induced polio occurs." Givens v. Lederle,
556 F.2d at 1346. It is important to note the court's observation
that these statistical reports were admissible as public records.
See Fed. R. Evid. 803(8).
Further, the Fifth Circuit found the
dOCuments could be referred to because the editor of the reports
was "present in the courtroom, identified the documents, and was
subject to cross-examinationo"
Id. at 1346; Cf. Fed. R. Evid.
703; ~ also State v. Clayton, 646 P.2d 723 (Utah 1982); U.R.E.
63(15).
The Reyes case also involved the admission in evidence
of similar materials. 498 F.2d at 1264
13
In this Court the respondent now argues that the post-1972
package warning inserts were properly admissible for rebuttal and
impeachment purposes claiming that counsel for Squibb opened the
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used by the respondent to improperly suggest that responsible
public health officials had already determined that Delalutin
caused birth defects.

The admission of these documents altered

the course of trial, required Squibb to meet this unexpected and
improper evidence and led to the substantial prejudice complained
of.

The only appropriate remedy which this Court can grant at

this stage of the proceedings is to reverse the judgment below
and remand the matter for a new trialo
13 (Cont'd)
door during his opening remarks to the jury by suggesting Delalutin
was both a safe and effective drug
Barson Brief at 31.
A
review of the trial record, however, shows that Squibb's opening
remarks about the role of the FDA were quite limited and, taken
in context, were appropriate in view of statements made by the
respondent's counsel in his opening.
Specifically, Squibb's
counsel, in answering charges that necessary testing had not been
performed on Delalutin before marketing by Squibb, responded
that:
o

The testing was in fact done, and in 1956 the drug was
approved by the United States Food & Drug Administration
for use in human beings for sale in our country, and
indeed i t was.
In her argument to this Court the respondent contends that Squibb
misled the jury by telling i t that the FDA had approved Delalutin
based upon safety datao
D.Ex. 803, however, demonstrates that
the FDA did in fact approve Delalutin for sale to the public in
1956 after a review of just that. As noted in Squibb's initial
Brief the FFDC in 1956 provided for the approval of new drug
applications based on safety data aloneo
52 Stat. 1040 and 10520
In 1962 Congress amended the FFDC to require the advanced submission of efficacy as well as safety datao
21 U.S.C. §§ 32l(p),
3 5 5 ( b ) and ( e ) .
It also should be noted that the package insert provided
with Delalutin before that drug was first marketed in 1956 was
approved by the FDA. 21 u.s.c. §§ 355(a) & (b) provides that no
drug may be marketed in interstate commerce without that drug and
its labeling first having been approved by the FDAo The respondent
is simply incorrect when she suggests otherwise.
Barson Brief
at 5.
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POINT II
THE JURY INSTRUCTIONS WERE AMBIGUOUS AND
PROBABLY MISLED THE JURY AS TO THE PROPER
STANDARDS TO BE APPLIED IN DETERMINING THIS
CASE.

This Court has determined that the elements which must be
established in a products strict liability case and those necessary
to establish a breach of implied warranty "are essentially the
same . . . .

Therefore,

the same defenses

discussed in strict

products liability are available under breach of implied warranty."
Ernest~·

1979).

Hahn, Inc. v. Armco Steel Co., 601 P.2d 152, 159 (Utah

The Restatement of Torts (2d) § 402A comments h, j, and

k, which deal with the application of the principles of strict
liability, dictate that in a prescription drug case the failure
to warn is to be judged by traditional negligence concepts.

That

duty, by definition, can only apply to dangers which the company
knew or should have known about through the exercise of reasonable
care.

See Squibb Brief at 56.
It is clear that because of the multiple, repetitive, and

ambiguous instructions which the trial court gave the jury, no
one can determine with certainty that the jury did not impose a
standard of absolute liability upo.n Squibb. 14

Apparently, all

14
The respondent suggests that the appropriate standards to be
applied in a strict liability case were given when the court
provided the jury with Instruction Nos. 23 and 24.
See Barson
Brief at 36. What is clear from the placement and content of
these charges, however, is that they dealt with the question of
negligence. Since the trial court charged all three theories and
provided separate instructions for each, this tended to emphasize
the incorrect strict liability charges rather than minimize them.
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the parties in this proceeding agree that it would be inappropriate
to judge Squibb based on such a standard.
Instruction No

o

25 which represents

a

strict liability

charge in the abstract, is completely inapplicable to this prescription drug case and, when read in conjunction with Instruction
Nos. 26 and 27, would appear to erroneously convey to the jury
that it could hold this defendant responsible should it find that
Delalutin caused the plaintiff's birth defects,
Squibb's ability to know of these dangers. 15

independent of

While such a presump-

tion may be appropriate under other comments to the Restatement
of Torts (2d) § 402A, it is inappropriate in a prescription drug
case.

When Instructions Noo 18 and Noso 25 through 29 are read

as a whole it is obvious that a jury may well have imposed liability
if it simply determined that Delalutin caused the birth defects
complained of.
The proposed Instruction which Squibb requested the trial
court give (Proposed Instruction lOA) eliminated these ambigui15

We agree with the respondent that the jury instructions must
be considered as a whole and no particular instruction or parts
should be considered separately or given undue emphasis. We also
agree that were the only flaw in these instructions the unnecessary
duplication or replication of an idea reversal would not be
required.
Actually Woodhouse v. Johnson, 436 P.2d 442, 445 (Utah 1968),
cited by the respondent, observes that while duplication of an
idea in the instructions is not reversible error it is best to
avoid repetition where possible. Here the unnecessary repetition
was highly prejudicial because its effect was to lead the jury to
assume that strict liability, breach of warranty and negligence
all presented different issues for their resolution. As we have
seen, this is simply not the case.
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ties by instructing the jurors that "you can find Delalutin in
question to have been in a defective condition, unreasonably
dangerous only if you determine that Squibb failed to warn .•.. "
Appendix B (emphasis added).
Rptr. 584

In Skaggs v. Clairol, Inc., 85 Cal.

(Cal. Ct. App. 1970) ,

a

California appellate court

found in virtually identical circumstances that the Instructions
were so ambiguous that "the jury could believe that plaintiff's
right to recover damages from defendant was dependent solely upon
showing .•. (defect)."
at 588;

Cf., Smith v.

Skaggs v. Clairol,
~·

Squibb~

(Mich. 1979); Ortho Pharmaceutical
541,

552

Inc., 85 Cal. Rptr.

sons, Inc., 273 N.W.2d 476

£2E.E.· v. Chapman, 388 N.E.2d

(Ind .. Ct .. App. 1979); Rainbow v. Albert Elia Building

Co., .!a.£., 373 N . Y.S.2d 928 (N.Y. App. Div. 1975).
The respondent has totally failed to address this serious
ambiguity in the jury Instructions.

Since Squibb properly objected

to the failure to give its Proposed Instruction lO(a) and since
the trial court's failure to do so substantially prejudiced the
appellant, it is entitled to reversal of the judgment and a new
trial.

See,

~·,

Quarry v. Waters, 588 P.2d 702, 704 (Utah 1978).
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POINT III
THE RESPONDENT FAILS TO ADDRESS THE ARGUMENT
BY SQUIBB THAT IT WAS ENTITLED TO A DIRECTED
VERDICT ON THE ISSUE OF TERATOGENICITY TESTING.

The defendant moved for a directed verdict on the first
count of the Complaint (negligence) as it related to negligent
testing at the close of the case.

Squibb observed that no evidence

had been produced to show that were animal teratology testing to
have been done i t would have probably provided information demonstrating the defects alleged (Tr.2440, 2442, 2596).

The applica-

tion was denied by the trial court. 16
The respondent has completely missed the thrust of Squibb's
repeated arguments that the issue should not have been presented
to the jury.

Each of the plaintiff's own experts observed that

there was no assurance or even likelihood that had animal teratology studies been initiated they would have disclosed Delalutin's
teratogenic potential. 17

See Squibb Brief at 70-72; l; Frumer &

16
Thereafter, Squibb objected to the jury instructions dealing
with negligence for the same reason (Tr.2578-2579). The defendant
later raised the issue when i t moved for judgment nov. and a new
trial after the jury's verdict (Tr.2595-2596, 2631).
Squibb
raised the issue again before this court in its initial Brief.
Squibb Brief at 66-72.
17
While Squibb has sought to avoid distracting this Court from
the important legal issues here, the repeated references in the
Barson Brief to masculinization or viralization requires some
response. Respondent, for example, refers to the fact that there
were numerous revisions in the physician package insert between
1956 and 1979.
Barson Brief at 5.
Many of these changes are
irrevelant to the issues in this case and deal instead with new
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Friedman, Products Liability § 601(1].
Appellate Division in Buria v. Rosedale
N.Y.S.2d 395,

397

(N.Y.

App.

Div.

As noted by the New York
Engineering~.,

184

1959), where a plaintiff's

theory involved a failure to test "negligence [is] still not
established unless it be shown that proper testing would have
disclosed the ...

(product] to have been defective."

(Emphasis

17 (Cont'd)
medical uses for Delalutin such as the treatment of endometrial
cancer (P.Ex. lO(s)), something for which the drug is currently
used.
However, insofar as the package inserts relate information
on the possible masculinization of female fetuses, they simply
reflect Squibb's efforts to report information as it became
available.
Sporadic cases of virilization, which can occur
spontaneously, in patients receiving Delalutin did not establish
a "cause-effect" relationship as noted in the FDA-approved package
insert of 1966 (P.Ex. lO(h)).
The 1970 revision in the package
insert did nothing more than make a more generalized statement
concerning progestins; it did not, however, change the earlier
statement that determinations regarding cause and effect were
"inconclusive" (P.Ex. 10(1)).
Insofar as masculinization is concerned, the evidence available
to Squibb showed that tests of Delalutin indicated it to be
non-virilizing and non-androgenic. Even Dr. Alan K. Done acknowledged that Dr. Leonard Lerner's study showing Delalutin to be
non-androgenic was a good one insofar as testing for virilization.
(Tr.769) Additionally, the plaintiff fails to note in her Brief
numerous other articles cited in this record which indicated that
Delalutin did not cause virilization or masculinization. Thus,
the many references to virilization and masculinization which
suggest that this has a bearing on teratogencity and/or testing
are misleading.
Indeed, the admission of substantial testimony
on masculinization, to which Squibb took objection, in all probability only served to further confuse and mislead the jury.
(Seen. 18 and.19 infra.)
One final observation is, perhaps, appropriate to highlight
the apparent confusion existing in the minds of plaintiff's
counsel.
They make reference to the testimony of Dr. Allen
Goldman and the articles which he cited to support the submission
of negligent testing to the jury. Aside from the fact that many
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in original) .

This expression of the principle of proximate

cause has been accepted by this Court in Northern v. General
Motors

.£2.!:E..,

268 P.2d 981 (Utah 1954).

18

17 (Cont'd)
of these articles deal with the question of masculinization,
several of the articles dealing with the subject of teratogenicity
are incorrectly cited by counsel as supportive.
Barson Brief
at 11-14, 17. For example, in the article by Andrews and Staples
cited by plaintiff, the authors concluded that:
"Our study on
MPA [Provera (another progestin)] did not support the clinical
observations of Nora and Janerich, for example, regarding MPA,
since no significant increase in gonad dipgenesis, heart defects,
or limb deformaties were seen after MPA exposure to any of the
test specieso" "Prenatal Toxicity of Medroxyprogesterone Acetate
in Rabbi ts, Rats, and Mice, 11 Teratology, 15: 25, 31 ( 1977). such
evidence hardly proves that the alleged failure to test was the
proximate cause of anything.
18
Squibb has focused on legal errors and has sought to avoid
drawing this Court into scientific discussions or arguments.
Plaintiff's comments concerning the so-called Deladroxate study,
however, require some response. Barson Brief at 400
The defendant had objected to the introduction of evidence
concerning Deladroxate, an injectable form of contraceptive,
composed of both estrogen and progestin (other than Delalutin)
and never marketed to the public (Tr. 751). The objection was in
part based on the fact that Deladroxate included estrogen, a
totally different family of sex steroids from progestins (Tr.749750).
Dr. Alan K. Done, as plaintiff's expert, had previously
testified that estrogens, which are very different from Delalutin,
were a potential confounding factor and that he had made an
attempt to eliminate studies involving estrogens (Tro869; 875,
876).
Nevertheless, the Court admitted P.Ex. 530 and permitted
Dr. Done to testify about the Deladroxate studies.
In discussing these studies on appeal, the plaintiff exhibits
a serious confusion which marks some of her other factual recitations.
See, Reply Brief at 23 n. 17 supra and 19 infra.
For
example, the study on rabbits did not reveal any "rabbit offspring
being born with their hind legs misplaced, their skulls misshapen,
and other skeletal defects." Barson Brief at 40.
Plaintiff has, presumably inadvertently, lumped together the
findings from the study involving rabbits with the findings from
a separate study involving rats.
"Perinatal and Postnatal Study
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While Squibb strongly disputes the claims that it should
have engaged in further animal testing with respect to Delalutin,
its argument that it is entitled to a directed verdict does not
depend on this contention.

There was insufficient evidence to

present the plaintiff's theory of negligence based on animal
testing because the evidence failed to establish proximate cause;
that were such testing done,
probably have been discovered.
on that issue.

Delalutin's teratogenicity would
Squibb was entitled to a verdict

Since the jury rendered a general verdict in this

case after the Court had instructed it on the theory of negligence
based on a failure to test, we cannot know whether the jury found
for the plaintiff based on this theory.

Under these premises

Squibb must be granted a new trial.

18 (Cont'd)
in Rats" (P.Ex. 530, P. 00036).
The study in rats was not a
teratology study.
In the rat study where the misshapen skulls
and other skeletal defects were noted, the Deladroxate was given
beyond the time when it could affect the development of these
structures. This was precisely the opinion of the authors of the
study who concluded that the malformations "probably were caused
by prolongation of gestation and/or intrauterine death" (P.Ex. 530,
p. 00041).
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POINT IV
THE RESPONDENT FAILS TO ADDRESS THE ARGUMENTS
MADE BY SQUIBB SUGGESTING THAT THE TRIAL COURT
ERRED IN:
(1) NOT EXCLUDING EFFICACY EVIDENCE
AND (2) PERMITTING P.EX. 58 WHICH CONTAINED
IMPERMISSIBLE SUMMARIES OF DRUG EXPERIENCE
REPORTS TO BE RECEIVED IN EVIDENCE.
A.

Efficacy Evidence

The respondent argues that efficacy evidence is necessary in
order to employ the.risk-utility analysis contemplated in comment k
to the Restatement of Torts ( 2d) § 402A.

For that reason she

suggests that efficacy evidence was appropriately received by the
trial court.

A review, however, of the Instructions given the

jury discloses that no information was provided on how this
risk-utility analysis should be employed.

Indeed~·

the record

reflects that the plaintiff never asked the trial court to charge
the jury with respect to the use of risk-utility analysis or the
application of comment k.
As is evident from a review of the Statement of Facts provided
by the respondent to this Court, efficacy evidence was routinely
confused with safety evidence. 19

It was also used to suggest that

19
The profound confusion this evidence must have caused as the
jury sought to resolve the issue of causation--a question of the
drug's safety--is exemplified by the Statement of Facts in the
Respondent's Brief.
Barson Brief at 9.
There, the respondent
suggests that two letters admitted in evidence over objection by
Squibb and written a year after Mrso Barson received Delalutin
forcibly demonstrate Squibb's indifference to teratogenic testing.
(P.Ex. 731; P.Ex. 736) What is apparent from a review of these
trial exhibits, however, is that they have nothing to do with
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Squibb had failed to engage in teratology testing--an entirely
different category of tests.

The plaintiff now asks this Court

to accept this efficacy evidence and apply a risk-utility analysis.
Accepting such an invitation would make this Court the ultimate
finder of fact and render trial to a jury a meaningless exercise.
19 (Cont'd)
teratogenic testingo Rather, both letters deal with the decision
by Squibb not·to fund an ongoing study at Johns Hopkins Medical
School testing the efficacy of Delalutin for another medical
indication..
As the evidence at trial amply demonstrated, it
would be highly unethical and improper to conduct teratogenic
testing on human beings and, of course, were the proposals to
have suggested such testing, Squibb would have properly rejected
them ..
In discussing Squibb's reluctance to undertake funding this
efficacy study, Dr. Kendall, then Associate Medical Development
Director at Squibb, noted that since his last visit to Johns
Hopkins University Hospital "the FDA has announced that i t will
publish a Federal Register Statement warning against the use of
progesterone in pregnancy .... Right or wrong, that is now the
FDA's opinion O••" (P.Ex. 731). Because of the expected FDA action
withdrawing Delalutin's pregnancy related indications as well as
various economic considerations, Dr. Kendall again wrote to the
physician conducting the study in September 1973 advising him
that Squibb funding for such an efficacy study was unlikely given
the expected FDA action. Again, rather than reflecting Squibb's
indifference to teratogenic testing, the letter demonstrates just
the opposite·. Dealing with the efficacy question, Dr. Kendall
observed:
Perhaps if work like this had been published
a few years ago, FDA would be looking at
Delalutin in a more favorable light.
Indeed,
from what you tell me there does seem a
chance even now that they will reconsider.
[P .Ex. 736]
The plaintiff's counsel, oblivious to the content of these
letter exhibits, erroneously observes that these exhibits "certainly establish the background and facts with respect to teratogenicity as they existed prior to the injection of Delalutin in
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Beyond a

few

isolated transcript references purportedly

supporting the introduction of this evidence,

the respondent

offers no basis other than conunent k for its receipt.

Instead

she seeks to distinguish Needham v. White Laboratories, Inc., 639
F.2d 394 (7th Cir. 1981), cert. denied,

U.S.

, 102 S.Ct.

427 (1981).

While the respondent is correct in observing that the reversal
was predicated on the improper jury instruction, it is undeniable
that the Seventh Circuit found that efficacy evidence was inappropriately received by the trial court.

That court specifically

observed:
The drug company's defense throughout
this case has been that it did not know of
the dangerous propensity of ... [the drug].
No warning accompanied the drug.
Thus,
comment k, by its terms, could not provide a
defense in this case ~ ... Because [the drug
company] failed to warn, comment k could not
apply in this case, and evidence of the
efficacy o"r inefficacy, of [the drug] ~
irrelevant.
[Needham v. White Laboratories,
Inc., 639 F.2d at 402]
Since the efficacy evidence was irrelevant and was improperly
used to suggest Squibb's negligence in failing to conduct tests,
19 (Cont'd)

Kathy Barson."
Barson Brief at 9.
Since this suggestion is
contained in the respondent's Statement of Facts under the heading
11
FACTS OF SQUIBB'S FAILURE TO PERFORM TERATOLOGICAL TESTS, 11 the
clear confusion in the mind of counsel for the plaintiff between
efficacy and safety testing demonstrates the serious prejudice
which can be produced when questions of efficacy are injected
into a case dealing with causation--a question of safety. Counsel
for Squibb predicted that such confusion was likely to arise in
the minds of the jurors should such irrelevant and potentially
prejudicial material be introduced in evidence (PR. 63-64).
Counsel for the plaintiff has now demonstrated how easily such
confusion can arise.
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this evidence "probably had a substantial influence in bringing
"

about the verdict

U.R.E. 4.

As such, Squibb is entitled

to a new trial.
B.

The Drug Experience Reports.

The respondent makes no attempt to seriously defend the
introduction of P.Ex. 58 containing a summary of inadmissible
drug experience reports (DER's) concerning Delalutin.

As noted

in Squibb's initial Brief, DER's represent anecdotal accounts of
experiences with drugs which are forwarded to drug companies by
various

individuals

including health professionals,

consumer groups, and the general public.
79-86.

lawyers,

Squibb Brief at 13 and

The law requires that drug companies routinely forward

these DER's to the FDA regardless of their source.
§ 355(j); 21 C.F.R.

§

21

u.s.c.

310.300.

In Muhlenberg v. Upjohn Co., 320 N.W.2d 358 (Mich. Ct. App.
1982), a Michigan appellate court recently found that DER's were
inadmissible hearsay and not subject to the business records
.
20
excep t ion.
The trial court also properly excluded the DER's on
20
The Muhlenberg court found that
The reports doctors submitted can be analogized to information procured in a survey.
Where surveys are submitted under the business
record exception to prove the truth of the
matter asserted, they routinely are excluded
as being nothing more than a compilation of
hearsay.
Unless the .techniques used in
conducting the survey are established scientifically and the survey results are objective
and representative of the pool survey, the
survey lacks the guarantees of trustworthiness.
[Muhlenberg v. Upjohn Co., 320 N.W.2d 358
(Mich. Ct. App. 1982)]
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that basis, however,

it then inexplicably permitted the witness

to testify as to their contents in summary form, in contravention
of U.R.E. 70.

Squibb Brief at 82-84.

The respondent incorrectly cites Needham v. White Laboratories,
63 9

F. 2d

at 403,

as

supportive

Needham holds to the contrary.

of this improper procedure.
There, the Seventh Circuit observed

that "before a summary is admitted, the proponent must lay a
proper foundation as to the admissibility of the material that is
summarized .. "
record,

639 F.2d at 403 ..

As is evident from review of the

such a foundation was not laid.

Since

the

summarized DER' s

Squibb Brief at 79-81.

produced virtually the only

implicating evidence against Delalutin in P.Ex. 58, it cannot be
said that the admission of such evidence was harmless.

Squibb is

entitled to a new trial based upon this substantial error.
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CONCLUSION

For the foregoing reasons, the defendant respectfully urges
that this Court vacate the judgment and remand the matter for a
new trial on all issues.
Respectfully submitted,
CHRISTENSEN I JENSEN & POWELL
Attorneys for Defendant E.R.
Squibb & Sons, Inc.

By:---'-!-_u...__/_ _ _ __
RAY R. CHRISTENSEN
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APPENDIX A

,•,

SAFETY ANO EFFICACY OF PROGESTERONE ANO

17~ALPHA-HYOROXYPROGESTERONE

FOR THE

TREATMENT OF REPRODUCTIVE OISOROERSo

An overview and

•ne po•en+:a1 benefits of progesterone and 17 hydroxy-

progesterone for trea""meni' of pregnan+ or potentially pregnant women was
presented by Willian Andrews, MeOo, a c:ommi't_'1'ee member, Oepar+ment of
Obstetrics and

Trea~en+

Gyneco I ogy, Eastern Vi rg t n i a Medi ca I Co 11 ege;; _-

of documented luteal phase

a hi"s+ory of

habi~ual

defec~

in infertile womeR and women

wi~n

abori'ion have achieved successful pregnancy with

adminis1"ratton of suppfemen1"al progesterone or 17-=0H progesterone..- - In a

double bltnd

s~udy

women with habitual abortion treated with 17-0H

prog9sterone had a 73% live biri'hs compared to 46% tn the placebo-group.

· In ~he· Fepor"~S cf~ i ng ~he t neff t cacy of progesterone supp I emen-rat ion for the
preven-!"ion of fetal was-t-age in women w·i'f"h
investiga~ors
crt~eria

~

his-t'ory of habitual abor-tion,

utilized either lowered pregnandiol levels for diagnosis, a

that varies with metabolism of progesterone, and started-progesTerone

'i-herapy aH'er +t;e

seven~h

week of pregnancy, too late -to expect benefii"s of

progesterone, or administered progestins that produce a luteolytic effect.

While progesterone is no longer employed for pregnancy testing,

tt~

use in

evafuaTfng primary and secondary ~enorrhea considen~bly Feduc:es 't't'H~.tLme anct

expense of diagnosis and •rea'i'men+o
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Those hormone prepara"l"ions wtth repor-fed terai'ogenicity are usuat.ly

es+rogen-progesterone combina•ion products.

Repori's of teratogencity with·

proges1"ins are derived mos1"1y from a I imited number of cases.,

The Collabora-t-ive Perinatal Project did not detec1' an associa-t-ion bei'ween
either progesterone or hydroxyproges'terone use and congenrtal hear-t- d1sease,
the VACTERAL syndrome, or limb reduci'ton, but did observe a

sign~fican"I"

increase of bir.,.h anomalies with medroxyproges"l"erone acetate-and noreth1ndrone

OespiTe +he Obs•etr!c and Gynecology Advisory

Corrrnittee':S.~ecommendation,-'fhe

Bureau of Drugs incJuded progesterone and hydroxyprogesterone among the
progesta•!onar agen.,.s

contraindica~ed

for use in early pregnancy.

Par1"tcfpants at 'the American Fer1"i I ii'y Associa1"ion sponsored symposium-

suggested thaT the human ova is exposed to concentrations of.endogenous.
proges1"erone and hydroxyproges1'erone in the ovary and during: transpor1" through
~he

hlJopian

+ube grea-t-er than the suggesi"ed therapeutic-doses, and there are

differences tn the chemical and biologi·ca·I effec1"s between of na1"ural
proges+erone and synthei"ic progestins.

Or. Andrews concluded

1-ha~

while medroxyprogesterone, norethindrone and

e•l'I i sterone may be 1-erai"ogen i c, he does no+ bel i eve that there is valid
ev i denc:e of proges~erone or 17 hydroxyproges1-erone. teratogenic i ty. and when-

properly indica•ed, use of these steroids are of significant benefit.

\

._/
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The biological activi+y of different sTrucTural classes of progesTaTional
agents was reviewed by Len Lerner, PhoOo, Qepar-tmen+ of ObsTeTric:s and
Gynecology, Thomas Jefferson Universityo

Whfle al I progesta1"ional agen-ts, Ca> s1"imula-t-e developmen-t' of

glands Cb> maintain pregnancy In some species of

endome~ial

ovariec~omized

animals, and

(e) exhlbi"" anti esi'rogenlc properi"les,, their o-ther physiologic ettects, i o-e-o
ancf"i.., androgenicsi ACTH s-timulation, cor1"isone I ike

ac:tivrry, are variable ..

The pr-oges'f-ai"fonal agen1"s are ac1"ual ly different cl asses of chemical compounds-·
wi~h

differen1' ra-t-es of me+abol ismjl excre-tion, and pa-tterrrs o_f ctiS'fribu'fJon_ in-

t n an trna I s-tud i es nore"f"h i ndrone and medroxyproges+erone, but- not

the body..

progesterone or Oelalu-ttn, have been repori"ed to affec:'f fet'al maseu-1 inizatlon.,-

lrtjec-tion of Oefali.rtfn

main~ained

pregnancy tn monkeys with i'hreatened

abOf""'° ion and no fe1'a I anoma J i es were observed anong rats_ 'treated wi ~h
proges.,.erone or Oe·I ah.rti n durl ng pregnancy.,

Franz Rosa,
commen~ed

~o0.

8 Qivision of Drug Experience, Food and Drug Adminis'fration,

on the adverse drug reac1"ions repor1"ed to the F-OA- an-d

epidemiologic: s-t>udies

•ne

concerning the use of progesta1"ional agents and

~ir'*'h

anoma I ies ..
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0..
\

·J

Qf the

computerized 120,000 adverse drug reactron reports ,..ecetved by the FQA-

there are about 700 terai"ologf cal obs@f"'vai'ions, 187
with progesi'fn COntafnJng drugs ..

o+ which are associated

Most of the gf9nftal defeci'S t"91)0r"Ted

Wef"'fl)

wtth Provera use, and many reports of anomal les attr-ibui"ed- to pr-og.,sttns wer"e
con•ounded with the us& o+ progestln and es1"rogen mfxtur-es.

stong

Whtie the grouping of case control and cohort studies suggests a +airly
r"'ef attonshlp

between fetat sex no-mone exposur-e and hypospadias, the lack of a

denominator pr-event's thP. calculatlon of an fncidence rate.
~ex

Tne assocfatioo

o~

hcrmones with hypospadfas Is ltmited to progestln exposure to comoination

with -estrog1tns, t .,e. gestest, oral contr-ac::epttves, and ts pr-obaoly due to the

tnf luence of esfrr.>gen r-ather than progestlnsG

The evldt9nc:e=a o'*' an assodation between non genttal malfor-matlons and exposure
to progestatlonal compounds was

~evtewed

by Robert Brent, M.o •• Ph.D.,.

Qepar-i'meni' of Ped r a1"r t cs, . Thomas Jefferson Un t vers I i:y.

Followlng concP.ptlon, there- ts a forty percent chance that a majo,..
mar 4 r.rmatt on or- anomaly. b rocheml cal or- anat°"!t cal, wl 11 occur. _The causes of
human mal •or-mat Ions ar-e multt factored.

Cytogenetlc err-ors acr;ount for about

5S of- anai'omfcal malformatfons, 20%. al""e duP. ·to autosomal gem:.tic causes and

65% are fr-om P.ftner a.multffactor-tal etiology or- spontaneous err-ors in
embr-yogP.ne~!s.

ThA ramalnlng 10% can be accounted 'or- by environmental

+actors, f .e. rn•ecttons,

ThP. I net dP.nce
drug r-eacttons
gr-19a+

"f

high dose radlatfon.

spec [+I c ma I +ol""matf ons cannot

r-Aport~d

~xpo!=urP. ~o

dr-ug~,

~e

detP.rmf ned •rom i"nP. advPf""se

to the Food and Qrug Admlnistr-atlon because o+

the dr-ug and the

commonnP.s~

o•

th~

th~

anomaly.
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Only one cohorT STudy, the Col laborattve PertnaTal ProjecT, associated use ot

progestattonal agenTs with

non-gani~al

negative sTudies with. regard

t~

malformation among many reported

non geniTal malformationso

Most of the

postttve data.originated from case c:on"frol studies 0 individual

physicfans

STudying a small populationo that perhaps ignored the significance of clinical

teratology and/or geneticso

Teratogenic

effec~s,

unlike muTagenic changes, exhibit a dose response

'threshold effec"f"; for exam.ple 9 The

app~arance

of an anomaly when the

e,q)erimen-t-al animaf has received 50-100 times the 1'herapeutfc

Some
~

)

~·

pcrren+i~I

doseo

errors in epidemiologic investigations of teratogentcity are:

the unknown incidence of a malformatfon, the low exposure rate of the
conTrols. ignoFing the Importance of the exposure period; Including in the
STudy malformations an etiology

unrel~ted ~o

the alleged teratogen1 ignoring

confound1ng hc:'f>ors and nega'i"ive .epidemiolog.ical s'tudtes-and. finally,

suggesTing· a causal tty tliai" doesn't make biological sense ..

In Levy's 1973 study some children were exposed
insul inf thyroid, the

au~hor

~o

other hormones, i.eo

also did not corroborate the date of-exposure and

used an tnapproprtaTe con+rol groupg

The Hal+rap

s~udy

ignored the negative effect of steroids on birth defects and

tn their pub I ications included the caveat

expected among babies born to

mo~hers

19

an excess of malformations would oe

with threa-t-ened or previous

miscarl""iages, whe.,.her or nc:rr they were given hormonesn ..
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The-Heinonen s-t-udy, on addittonal revfew, indicated tha-F 5 of the 19 cases of
cardiac anomalies were exposed after the period of cardiac organogenesis: wni le

some eases of malformation sugges't the involvement of envJronmen-tal or gene1"-icfac:Tors.,.

In a recen-t- publica-t-ton Nora s+ated tha1" memory bias may have affected his_- -da~a, and Or.

aren't' suggesi"ed or. Nora's use of an inappropria.te con1"roJ group

and method of analysiso

In summarizing the I i~errure, 1"here are many more repor-t-s
demons1"ra?e

than dido

0

an association of steroid hormones with non

None of the claimed posi•ive

par-t-icular -type of hormone.

that~ -di~

gen-i-t~a-1

no-t-- - ~

maltor~J'Jon

_-

associa1"ions were related to a -- -

The populcrtions si"udfed were smaJI ·in compariso_n

To the 1-o"!"af number of exposures and •he per lod of exposure- dur i-ng ges1"-a1"i on,
when exogenous hormone exposure was

pos~ibly

associated

wi~h JTtal_forma~ion-,

was=.

1-oo broad for induc+fon of 1-he repor-!"ed mal forma'tions • - There was no
cons i s+en'+' type or pattern of def ec+s or any ind i ca1" ion _ot a dose- response

rela1"fonship.,

There is data sugges'ting thaT bleeding

in

early pregnancy and

aborTfon are themselves associai"ed wi'i"h an increase of

Cessa• f on of 'the use of

s~ero f d

~hraatened

malformed -i-nfani"s-.

pregnancy 'tests has not had -an effect on the

overal I number of reported malformations.

The criTeria necessary -t-o establish an agen1"'s teragogen-icity are:

I.

A majority of the epidemiological

s~udies

must

demons~ra~e

an increased
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Incidence of malformattons tn the exposed population.

2 ..

The eptdemlotogrc

parTtcular group

3 ..

s1"udl~s

ot

should demonsi'r'ate an Increased Incidence ot a

malfor-mattons, t.ec

rubella,

thalidomide.

It should b8 posstole to demonstrate t~atogeniclty in an animal

model,

except for vfrusesc

4 ..

Th94""e should be some type o+ a dose
P.xposurl! and the drug,, 1.. eo

accomp ant P.d

5~

· The

rela~lonshlp

an Increase tn

the

bet'llJP.en the amount

o~

dose ln animal -studies- is

an t no-ease t n t net denc:e .,_

by

There must bP. a scJentittc: explanation for the eff4'Cta

eurFeni' data as sod at-1 ng progesterone as ~ ter=- atogen does not meet the

above crtter-ta.

It Is dlHlcuit to consider" progesterone as a

ter-atogen

because o• thP. h I gh prog.esterone 1eve t s to wh I ch the embryo i s exposed dur i ng

deve I opmen to

The current' labP.I Ing

~or

proges1'ationat dFug pFoduc:t's should be more specific,

and cl tntcat ly appFoprtate.

QI"".,- Br=ent Is convinced that progesterone and

17-0H progP.i:ctEYonP are not ter'atogentc and th& F(sk associ.at_eid with '!'hP.ir use
-Is I ess than the spon-raneous Ft sk with TnadvertP.nt usP o'- oral contracept Ive
Jn f!ar'" t y pr-egnaney

Or.

$

Brent' ~uggP.sted lab~ltng changes ~or progestatlonal drug products shculct
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-atnc:Jude the s1"a1"ement': "Although This drug has no-t- been proven safe for the
developing embryo, the risk of embryo or fe1"al pa-f"hology with therapeutic
doses would not warr-anT- an f nt'erruption of pregn·ancy in a -wanted pregnancy
since +he

spon~aneous

,..isks are much grea-t-er".

Or .. John Rock, Johns Hopkins University School of
epldemiologic da1"a from

~hree

hundred

pa~ients

~edfcine,

pr"eseni'e~

-t-reated with progesterone or

f7-hydroxyprogesterone from the tfme of the elevation of basal body - -temperat'ure and c:on1"inued for six weeks or, in some cases, througnou1"-tne

entire pregnancy.

0

He compared the ra+e of

and was unab f e to de1"ec1" a

sf gn if i cant

VACTERAL syndrome, or

reductions.

J tmb

bir~h

anomalies-to a confrol- group

number of chi J dren wi ttt e i-fner

- The eff icac:y of progesterone and Ii-OH progesterone caproafe
the onse'f'> of prema1"ure labor,, the e-tiofogic

fac~ors

~for

assoCiated

--tne

preventing

:wii"n

pret-er-m

I abor and '!"he -t-eratogen i c risks of this therapy was d t scussed by ·John Johnson,
~.D ..

,, Johns Hopkins University Medical Schoolo

A medical his-tory of pre"f"erm delivery and of repeated spontaneous miscarriages
is us_ual ly associated with l"'isk of additional preterm delivery in subsequeni'
pregnancies.

In a prospec:1"ive double blind placebo control led study, treated patients had
less preterm def iveries, greater bir+h weight babies and a fower perinatal
mor1"al ity than

~he

con•rol group.

u
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The difference tn the rate of prematurity during a second study of
un~reated

t~eated

and

pa.,.ien.,.s was less than differences between trea•ed and placebo

control led patients, perhaps due to the beginning of trea-mtent after the
sixteenth week of pregnancy and limiting the amount of medication to 250 mg/
week o

In a doub Ie b I f nd prospect- ive si'udy of pat Ien'i"s treated with

17-hydroxyprogesterone, women carried their pregnancy slgnlficantly longer and
had grea'f"er bir"l"h weight babies than women treated wi'th the beta agonist'

ri+odrineo

In an attemp1" to det'ermt ne the effects of. 17-0H proges1"erone, no- differences

in serum levels of es+rogen, c:orticoids,

epinephrine~

norepinephrine, 17 OH

proges.,.er-one or pros1"aglandin metabolites were identified among ei't'her term or
preTerm del lveriesc

However» the serum levels of .progesterone and urinary

pregnandiol were significantly lower prior to preterm del fvery suggesting an
etiologic role of progesterone..
be~ween

T-rea1"ed and un•reaTed

The

tc:r~-al

pa•ien~s

frequency ot congen·ital· anomalies

at high risk for pre1"erm dei ivery is

simf lar w·i+h no chromosomal or congenital anomalies observed ..

Or .. Johnson be Ii eves
proges•a~ional

drugs for

~hose
~he

consider

agen~s

tna-r the

Food and Drug Admi n i s"N"a"f ion rs conterrt ion 1"hat

are teraTogenic had hafted research with this class of

ind i c:a1" ions and he expressed •ne hope that the comm·i t~ee wi I I

new da+a under recommendai"fono

Ron Gray PhoO., Oepar1'men+ of Population Oynamicsp Johns Hopkins Hospital,
6

reviewed the li1"erature of the teratogenic potential of progestin, the
etiology of

bir~h defec~s,

the clinical use of progesteronep and the

inconclusiveness of epidemiologic studiesa
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A human tera1"ogen can be i dent it i ed by an abrupt increase irt i"he incidence- of
a par-t'icurar detect coincident ~i.,.h a known environmen1"al change during early:
pregnancy with the absence of o1"her factors common to al I o1"her pregnancies

which yield infants wfth characteristfc defectse

Cf inicaf exposure +o proges1"in compounds,. nai"ural or synthetic. in early
pregnancy may be due to con1"raceptive hi I ure,. Treatment for I u'teal phase
defec+., pregnancy 'f"ests or' adminis-t-ration for the preventfon--of tnraai"ened abortion or prema+ure labor.

To de+ermt ne teratogenic etfec-t- of proges-t'erone compounds The exposure mus1"-_

0

coincide with a c:r-ttlcat phase of fetal development, women mus_t be

awar~

of

-the drug used, the cta-!"a mus1" noi" be grouped in an arbitrary fashion and confounded wi'th multiple rfsk fac1"ors,. l.eo., age. geogr-ap_nic 1-oca-tion.- 'the -use
of oTher drugs, and exis+ing medicaf conditions, mus"!" be accoun1"ed

tor.

The rne"f"hods of epidemiological experimental design are: CI:) the case- control

study in which exposed children are ma1"ched wi'th contr-of children contains
re+rospective uncertainty and has potential recal I bias C2>a prospective
cohor1" study investigates the frequency of abnorma I pregnancy among group_s of ·

women identifted as they enter the s'tudy a't 20 weeks and require a large study
popula.,.ion in order to detec"f" rare abnormalities.

C3> case series observ~ a

select group of abnormal pregnancies but without comparable information on

normal women and without a denominator and (4) clinical trials

u
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where, tn additton to eonfoundtng be"hi#een

Threatened abor~ion, the sample size is usually too smal I to detect uncommon
ab norma I t t t es o

Or .. Gray reviewed 't"he epidemiologie studies 't'ha"f> associate bir1"h defect's "'1i1"h
proges.,.tn

use and poin-ted out their shorteomings.11 i .. e. confounding., lack of

accurate drug hf story, drug use, biased information gatherJng, and- accuracy of

The levy s+udy of cardiovascular defects dtd not provide- information of the
spec.ifte na+ure of s~erotds used or a careful analysts of the indications for

drug usee

)

,

congeni~al detec~s and cases of

Thts and other studies estimate an unproven risk associated with .

estrogen and progestln use In c:cmbinatfon of about 1.5 to 2 fold.

The i net dence- ot. mascu I in i zati on of 1-he fema I e fetus ~ssod ated wI 'th

in'f-rauterine exposure
as abou't" 1%o
vi~f

~o

steroids.

whil~

difficult to

ev~l~at&.,

is estimated

i

v·ery high· doses ot proges1"ins -for sufficfent dura'tion may cause

I iza"f>ion bu-t- i't" ts unclear if the risk of· hypospadias or o1"her

geni~o-urinary

'

abnormalities is increasedo

If they do, the risk ts likely to

be exceedingly smal lo

From several published reports i t seems uni ikely that proge-stins signiticantly
increase the risk of neural tube defectso

}
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In the case

of

I imb defects, the Janerich estimate o~ a relative risk of 4o2

is difftcult to evalua-te due to recalJ bias anc inadeqa-t-e.control of
confounding

f~orsc

The reported VACTERAL syndrome in the Nora

report·canno~

be considered conclusive due to· a confused experimental design, recall bias,

confounding, and arbitrary grouping.

The Cooperative Perinatal Project did

not observe an assocta•fon between limb reduction defects-and intrauterine.
exposure "!-o proges1"lns.,

The·s+udy of non specific chromosomal abnormalities among induced abortions-or
new born

tntan~s

exposed to oral eontracepTives

producad·nonsignifican~c

resul+s wi-thou1" evidence of an assocta+ton be1"ween hormonaf exposure and
Down's Syndrome.

0

White

of

unproven, "fhe li1"eraTure suggests there may be a less than two-fold risk

cardiovascufar defec:Ts assocta-ted wi+h exposure to pr-ogestins•

This.risk,

however, is insufffc:ien1" to prohibit the use of a beneficial Therapy.

Or.

Gray cone: I uded tha-t -t-ne ep i demlolog i cal ·da1"a Is confused, Inc:onc Ius ive and, ai"

+he bes"f",, only suggestive.

Anne Wen"f"z, M.Q., Oepar-tmen-t- of Obstetrics and Gynecology, Vanderbil"f
Unfversii"y, reviewed ovarian fol ltcuJar developmenrt', corpus
early pregnancy, the

~iagnosis ~nd

lu~eurn

func-t-ion in

the role of progesterone Therapy for

1"rea-tinent of lu1"eal phase def icfenc::y •

.

_)
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At about day 25, an increase in fol ltcle stimulating hormone CFSH> stimulates
fol I lcle growth and emergence of a primary fol I icle accompanied

by

granulosa

eel I hyperplasia, an Increase tn FSH and luteinizing hormone CLH> synthesis of
LH

~nd

FSH receptors and of the aromatase enzyme for conversion of androgens

to estrogeno

The increase in peripheral concen'tration of progesterone and

es1'rogen s1"imulates +he pre ovula-tory LH surge preparing

the follicle for

progesterone synthesis and the re-initiation of oocyte maturationo

ovula·Mon, a+ the mf·d and la1'e fol ltcular s1"a1"e, and during

~ubal

Prior to
transpori",

the ovum is exposed 'i"o elevated proges1"erone concen-t-ratlon ..

The primary func-+-i ons of progesterone and 17-0H progesterone are the
establishment of a secretory endometrtum and to prevent rejection of
trophobf astic tissueG
proges~erone

Since the peripheral progesterone and 17-0H

levels decrease after ovulation and remain at lower levels unti I

the produe'+' ion of p I acen-t'a I proges-terone 9
supplemen~ation

abet.rt day s i x-ty of pregnancy,,

of progesterone is needed before the m-issed menses and before

pregnancy is first detectedo

Firs~
lu~ear

identified by progesterone deficiency and later by endometrial biopsy,

phase defect occurs in 3-5$ of infertile women, anong anovulatory

clomiphene

~reated pa.,,.ients~ wome~

in chronic a'fhletic training, and is

associated with infertility and recurrent miscarriage.

The concepT of luteal

phase defect has recently been extended to an endometrial target tissue
incapable of allowing

ov~~

implantationo
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Progesi-erone suppos l ~or- i es, Z5 mg twice da r' I y, star1-ed after an increase in
basal body 1"empera1-ure and con1"inued un1"i

J

menses or in'i"o_ early pregnancy_

achieves-Jevels noi" in excess of those observed during the normal lu'teal phaseo

In a- S'tudy of six hundred cases of primary infer1"i I ity, 'fhe_ IL.rl"eal phase
defec't was ldentffled fn thir-f"yor;>three women as the sole cause- of infer·M I ity_
and trea'tment with progesterone resulted in a cumufa'tive -pregnancy rate of 50%0-.·

Charles Hanmond, M.O .. , Oepartmen't of Obs-t-ei"r-fcs and Gyneco-logy, Duke- -

Un iversi'f"y Medi cal center, defined I u<f"ea I phase def I c i ency as- an- abnorma I i -ty.

of 1-h.e corpus lu'teum si"eroid producing mechanism manifes-ted eJther by
decreased proges~erone levels and/or brief luteal phase durcrf"::i.on, diagnosed- in

0

several cycles by endometrial biopsy, serum progesi"erone_ -levels and basal body'tempera"f>ure changes.

Wht Je ~here are no randomized con-trol s1'udies. luteal phase defects are

treated- with 25 mg vaginal proges1'erone supposi+orfes tw-ice daily ·unt_i I either
onse'f" of menses

or

diagnosis of pregnancy and continued un1"-i-I -the- I O-J 2'th· week

of pregnancy.

Successful pregnancies occurred with either OelaJutin supp:lemen""tation, 250-mg
once per ·i11eek,

or no "f"reaimen1". with no

fe~a I anoma I

i es observe<t i-n- -tr-ea"f"ed

pa"t'f en~s ..

\.__)
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Or. Hannond believes luteal phase defect extsts anong some patients and
treatment with 2S mg progesterone suppositories approached the physiologic
concentrations observed during the luteal phase wiThout a teratogenic risk.

Or. Reddick, M.D., University of Connecticut College of Medicine, reviewed his

da-t-a on prolactin as a possible biochemical marker of progesterone produc"fion.

Prolactin is synthesized .2!,
endome~ial

~

-tissue from about

day

Tn pregnant, cycling, and non pregnan-t24 of the mensiTual cycle and may be

considered a biochemical marker for progesteronea
production ts increased

by

In vitro prolacttn

proges-t-erone but inhibited

by

estrogen, suggesting

es'i"rogen as a possible cause of an endometrlal matura1"fon detect.

Luteal phase defect ts dfagnosed by endometrial btopsy in two c:ycies and
trea•ed

wi~h

25 mg proges-terone

.suppositoFi~s

congenttal malformations anong eighteen of
nave

twice daily e

twenty~two

de I i vered· w-i -th 5 spon'i'"aneous ear Iy mi sc:arrf ages.,

only fmpor+ant for his1"ologic: ma<f"urcrtion of 1-he

biochemical

ae~tvi't"y

of that tissueQ

. There

were no

treated pregnancies that

Progesterone is noi"

endometrium but for the actual

He believes identification of a hormonal

deficiency +haT prevents implantation and early embryonic development

necessi•a•es treating •hat deficiencyo

The

tera~ogenic effec~s

of progesterone therapy in a large private practice

was presented by Joseph Festep MoOG. Department of Obstetrics and Gynecology,
Saylor Unive:si+y Cof lege of MedicineG
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1T'Aa1inent consisted of

?r"ogP.~~erone

rlsP. In

ba~at

vaginal

body tP.mpP.ratur-P. urrTif

~he

suppositories three days

a+~e".'.

36i"h day sincP. thP. last menstrual

period folfoWP.d by 17 hydroxy-progesterone until the 50-601"h day o+
pregnancy.

The 1150 wcmen tr-~atP.d

witn Oelalutin +or various !ndfcai"icns, _and __

2700 matche:td. con'h-ol patients, were o• comparable age, gr-avidity and partty,
rt=tcPived '?5o-:;oo rng/triject!oo mos~ly weP.kty fO'· +r-om 1-20 weeks ol pt:"egnancy.
The tnc:tdenc:e of cor.igenttal

an(')ma I t P~ wP.rP. ac;soc t atAd

mul1"fvrtate anomal f P.45 was 14.7/1000 In treated

with h-ert d f sease t'hat cou Id poss lb t y bP. attr:- i buted

0
J(')urna! Qbstetr-tcs and GynACotcgy 141:567, 1981>, Gr-ay and Shardein_

17-0H p,..ogestP.f'"'one for the

~·ud f Pc;

bP

t nv() t VP a

r-Aa~onable ~n

WP

tr'eatrm=tnt of r-epr-oductfvP

I I dP+ I nPd c I t n i ca I

conduc-t 'ur-thP.r

dlsor-(J~s.

and endocr- i no I og I ca I patt ~n1"

~tudf P!' wi~h po~iTivP

contr-ols, to det...-mi11P

t t~ ,.u i c acy •

u
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The committee recommended labeling changeso

The amended label should indicate

thaT progesterone and 17-0H progesTerone do not appear to have any significant
teratogentc potenttal and the current labeling, suggesting teratogenic
po~enttal

of sex hormones, be modifiede

The recommended dose of progesterone for luteal phase deficiency should be
ef-ther

proges-ter·one in oi I 12 .. 5 mg daily in'framusc:ul arly or 25 mg

suppos icfoor i es i'w ice da i ly, either vagina I ly or reci'a I ly o

The eommi-H-ee does

no~ curren~ly

have enough data to documenT the absorption

characteristics of tntravaginal progesterone To establish a dose leveio
However, "a maximum dose of 200 mg daily for fourteen days should not be
exceededQ

Addi+ionai information fs needed +o determine the relationship

be1-ween various doses of progesterone and

resu!~tng

serum levelso

ATG/sn/12/25/81/32.558
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ORAL CONTRACE?TtVE LABELING

Llnyd MlllSTPfn,

?h.Do.

Oepu~y.QirPCtor,

Qtv!sion ~f Qrug Labeling reviewed

the JunP. 1979 Food and Drug label Ing regulations and l""P.qulramP.rr!·so

ThP. labPltng

of drug product's choufd prP$Prr,_ accu,.ate, easy to r-ead. non

promntfonal fnformatton that ts not mlsleadfng and is wfThout implied claims
rye ~uggP.ct f on~ of d,...ug use whN"e there ts l nadequate ev I dence.

o+ sa+ety anct.

pffectlveness ..

The marn sections ot '!"he label irig ar-e Indications, w_arnings, precaµtloos,

advP-rse reactions and dosage which provide guidance for safe_ and intel I igent

0

USP. o~

thP.

p~oduct.

T~P pcT'po~P.~

of

for the safe and

th~

packagP. labP.ling are (1) to provide adequate informatlon

ef~ecttve

use o+ the drug <2> to act as an educat!onat

rnr.rum-tnt r-egar"dfng a specf!+tc drug an.d C3> to pr"'ovtdP. the__fac"hlal basis and
th~

ttmftatfons tor the promotion of drugs tn thP. medlcaLcommuni"!"y.

ThP. l ntent o-f the rev I SPd t abe I f ng Is to de 1.ete somP. comp I ex, d 1tt I c:u l t to

read. r-epetlt!ous Jnformatfon. to Include new Information and to tar-get areas
that requtrP. further rPvf Pw and discussion.

The committee Is r-F.tquAsted to review and comment on the pr-oposed changes and
prov f dP. the best poccs I b IP. I abP. I Ing +or th I~ I mportan~ gr-oup ot drugs.

u
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The FDA tabeltng

,..~vision

?rograrn states that al I marketed product label Ing

must mePt the •or-maT and content of the new

~Agulation ~Y

November 1984, the

or'al contracP.pttve labetlng ts due May 1st 1982 and has an effective date of

To facJ I ttate r"'evtew. the

cur'rent label tng was divided into sections and

Card tac
Howard Ory, MoOo

Wiil lam Andrews,

~oOQ

Cerebr'ovascutar
Ralph O'Agosttno, ?hoOo
Phil Cor"+man, MeOo
Hetnz Bef"'end@S 1i M.. Oc

SP-Zar' Aksel, MoOo

Gordon Avery. Mo00@ PhoOo
Wt I I tam AndFews, MoO.
'

CT a I Contracept Ive

Genera I:

.

E~ ~

tcacy

Chypertens ton, ga I I b I addef"', ectop le prP-gnancy, d I abetes)

Ron

Nelson~

M.Oe
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Labora1"ory Tes1's

Wllltam Easterling, MoO.,

The c:cmmlttee will review tne proposed changes. recen'tly·publisned-r'epor"fs,
and

dtscu~s

these 11

in open session at a February meeting.

I certify tha~ I ai"tended 1"he November 5,5, 1981 mee1"ing of the Fer--tiiii"y and
· Ma-t-ernal Heal Th Drugs Advisory Committee and that 1-hese mirurtes adequata~y _

Feflec:t the proceedings.

~

--1/

.

._~ . c '-'-~ rU..i....tt..:. . ~'"'~-

(j

oav id Arch-er, M.0.,
Chairman

·

"\

t~;.:./' r. ···~ z

l

_..,,,,,.

._, I

.

:-j.

•. / 1 .J;
_ oa-re

A., T. Gregoire, --Pn;;-o ...

Executive Secretary

ATG/em/1/4/Sl/31559

..
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INSTRUCTION NO.

if2.t_

. You can find the Delalutin in question to have been in
a defective condition unreaaonably

d~gerous

_only if you deter-

mine. that Squibb. failed to warn of a. known danger
in the use of
. .
the Delalutin, or a danger which
should have·
been known iiven the
.
-

.

·.·

•"-•

o

•,.'.,4>1_-: :"'

-~•••

•O,.&.P

•. . . . . . .

state of· technological development at the time the drug was
administered to lCathleen Barson in 1972 •.

-------------------·-·- ·--

.

···- ···--- ..

RESTATEMENT (SECOND) of TORTS §402A Commencs j_and k;

Ernest W. Hahn Inc. vs. Armco Steel Co., 6.01 P2d 152. (Utah.

19-79) •
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